PROGIS
Following recent changes in Google's geographical product strategy, Progis offers Youmaps, that leverages the power of Google Cloud Platform in an integrated solution.
At the Google Global Partner Summit to be held in San Diego from 23 to
25 February 2015, French company Progis will present its new integrated
geographical platform for businesses.
Progis, an expert in
integrating geographical information systems and a Google Premier
Partner, now has an innovative platform. Its features include customixed
map creation functionalities in collaborative mode to share or to
incorporate into other applications, easy geographical data handling and
the fast execution of complex spatial requests via an intuitive,
easy-to-use interface.
Google Cloud Platform's evolving infrastructure offers all Google's storage space and development capacity, tailored to web, mobile and backend solutions. Google Cloud Platform provides businesses with a 99.9% service level agreement and strong performance: average network latency of 57 ms, auto-scalable up to 7 billion requests per day.
Progis is expected to achieve swift sales growth by marketing this innovative SaaS platform.
" We have considerable know-how in geographical information technologies. We are very proud to be working together with Google's teams: we share the same vision of making technological innovations easy to use, " says Nicolas Fenard, Associate Director at Progis.
With the Google Global Partner Summit, American and Asian markets are opening up to this French small business…
About Progis:
Progis is an expert in integrating geographical information systems, a
Google Premier Partner, and has already been the recipient of awards
from Google in San Diego, two years running, with the EMEA Partner of
the Year award.
In September 2014 Progis joined the Devoteam group.
Devoteam is a European leader in cloud solutions for business. The
Devoteam group has consolidated its position on the digital
transformation market, primarily through Google solutions.
About Devoteam:
Devoteam (Paris:DVT) is an information and communication technologies consultancy group set up in 1995, and a leading partner in IT transformation for its customers. By combining consultancy and technological solutions, Devoteam can speed up the transition of its customers' services to the cloud and to digital.
Devoteam's turnover in 2013 was €453 million and it currently has 3 600 workers in 20 countries, in Europe, North Africa and the Middle East.
Devoteam SA (DVT) is listed in Compartment C of the NYSE Euronext Paris exchange (Code ISIN: FR 0000073793), and is on the CAC All Shares, CAC All-Tradables, CAC Mid Small and CAC Small indexes.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
Contact:
Press contacts:
Devoteam
Isabelle
Lovett, Tel: + 33.6.69.58.29.03
isabelle.lovett@devoteam.com
or
Agence
Ketchum
Aurélie Chambon & Bastien Rousseau, Tel.: +33 1 53
32 56 88 / +33 1 56 02 35 05
aurelie.chambon@ketchum.fr
/ bastien.rousseau@ketchum.fr
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum